Overall, our current study, together with previous in vivo and clinical evidence (72–75), suggests that IL-1β and NLRP3 actively function in promoting senescence of astrocytes and could be valuable diagnosis biomarkers and therapeutic targets for AD. Here, NLRP3 is linked to Alzheimer disease.